Williams Pete A, Harder Jeffrey M, Foxworth Nicole E, Cochran Kelly E, Philip Vivek M, Porciatti Vittorio, Smithies Oliver, John Simon W M
The Jackson Laboratory, Bar Harbor, ME 04609, USA.
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Science. 2017 Feb 17;355(6326):756-760. doi: 10.1126/science.aal0092.
Glaucomas are neurodegenerative diseases that cause vision loss, especially in the elderly. The mechanisms initiating glaucoma and driving neuronal vulnerability during normal aging are unknown. Studying glaucoma-prone mice, we show that mitochondrial abnormalities are an early driver of neuronal dysfunction, occurring before detectable degeneration. Retinal levels of nicotinamide adenine dinucleotide (NAD, a key molecule in energy and redox metabolism) decrease with age and render aging neurons vulnerable to disease-related insults. Oral administration of the NAD precursor nicotinamide (vitamin B), and/or gene therapy (driving expression of , a key NAD-producing enzyme), was protective both prophylactically and as an intervention. At the highest dose tested, 93% of eyes did not develop glaucoma. This supports therapeutic use of vitamin B in glaucoma and potentially other age-related neurodegenerations.
青光眼是一种神经退行性疾病,会导致视力丧失,在老年人中尤为常见。引发青光眼以及在正常衰老过程中导致神经元易损性的机制尚不清楚。通过对易患青光眼的小鼠进行研究,我们发现线粒体异常是神经元功能障碍的早期驱动因素,在可检测到的神经变性之前就已出现。烟酰胺腺嘌呤二核苷酸(NAD,能量和氧化还原代谢中的关键分子)的视网膜水平会随着年龄增长而降低,使衰老的神经元易受疾病相关损伤的影响。口服NAD前体烟酰胺(维生素B3)和/或基因疗法(驱动关键NAD生成酶的表达),无论是作为预防性措施还是干预手段都具有保护作用。在测试的最高剂量下,93%的眼睛未发生青光眼。这支持了维生素B3在青光眼以及可能的其他与年龄相关的神经退行性疾病中的治疗应用。